Glaxo Gets OK to Expand Marketing of Inhaler Drug

April 30, 2015 7:47 PM

58 0

GlaxoSmithKline plc says it has received U.S. approval to sell its once-a-day respiratory inhaler Breo Ellipta for a new use in asthma patients ages 18 and older.

The expanded approval from the Food and Drug Administration will help Glaxo replace sales of its best-selling product, Advair, which faces generic competition in Europe and pricing pressures in the U.S.

Read more

To category page

Loading...